Monoclonal Antibodies Targeting Amyloid for Alzheimer Disease

In this interview, dementia expert Gil D. Rabinovici, MD, discusses monoclonal antibodies that target beta-amyloid–-including a recent phase 3 trial of donanemab published in JAMA-–and reviews considerations for their use in patients with Alzheimer disease. Related Content: Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease https://ja.ma/45fl0b5 Donanemab in Early Symptomatic Alzheimer Disease https://ja.ma/3DN6YBQ Podcast was originally published on August 3, 2023. https://edhub.ama-assn.org/jn-learnin... --------------------------------------------------------------------------------- Follow JAMA Clinical Reviews on: Youtube:    • JAMA Clinical Reviews   Apple Podcasts: https://podcasts.apple.com/us/podcast... Spotify: https://open.spotify.com/show/229VuDi... Pocket Casts: https://pca.st/3ghw Your podcast app of choice: https://pod.link/1027430378 Website: https://jamanetwork.com/journals/jama... --------------------------------------------------------------------------------- For more from JAMA • https://www.jama.com •   / jamajournal   •   / jama_current   •   / jamanetwork   Follow the JAMA Network • https://www.jamanetwork.com • http://www.jamanetworkaudio.com •   / jamanetwork   •   / jamanetwork   •   / jamanetwork   •   / jamanetwork